AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36100795
Drug: IV 400
RxNorm normalized name: VPRIV 400 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 400 mg ibuprofen
Trial: 36100795
Drug: IV 20
RxNorm normalized name: TPIV 200
DrugBank: TPIV 200 (DB17318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 20 mg tenoxicam
Trial: 34384882
Drug: Continuous letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous letrozole (2.5 mg/day for 5 years)
Trial: 34384882
Drug: Intermittent letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent letrozole (2.5 mg/day for 9 months followed by a 3-month interruption in years 1-4 and then 2.5 mg/day during all of year 5)
Trial: 32114186
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment
Trial: 32187503
Drug: 4D-calculated dose
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4D-calculated dose
Trial: 35644931
Drug: Tradipitant 85
RxNorm normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tradipitant 85 mg b.i.d. for 9 days
Trial: 33187948
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg oral amoxicillin before and after surgery
Trial: 33187948
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg oral amoxicillin after surgery alone
Trial: 35576560
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (patient education and exercise therapy using a mobile messaging app)
Trial: 35576560
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (usual medical care with pharmacological treatment)
Trial: 33864917
Drug: Oral hydroxychloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydroxychloroquine (400 mg once, followed by 200 mg/day)
Trial: 33864917
Drug: Povidone-iodine throat
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine throat spray (3 times/day, 270 µg/day)
Trial: 33864917
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc (80 mg/day)/vitamin C (500 mg/day) combination
Trial: 33864917
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (12 mg once)
Trial: 33864917
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C (500 mg/day)
Trial: 34417274
Drug: 7-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of oral amoxicillin (according to WHO weight bands) provided by community level health workers (CLHWs) in intervention clusters.
Trial: 34417274
Drug: Standard community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard community case management (assess and refer after pre-referral antibiotic dose) in control clusters.
Trial: 35215507
Drug: Maternal hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal hemoglobin concentration 100-110 g/L
Trial: 35215507
Drug: Maternal hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal hemoglobin concentration <70 g/L
Trial: 35215507
Drug: Maternal hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal hemoglobin concentration >130 g/L
Trial: 35215507
Drug: Maternal hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal hemoglobin concentration <70 g/L or >130 g/L
Trial: 33368237
Drug: Structured delivery
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured delivery preparation education
Trial: 33368237
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no structured delivery preparation education)
Trial: 33270142
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear treatment for 2 years
Trial: 32093635
Drug: High sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sensitivity for type 1 algorithm (ratio of type 1 to type 2 codes ≥ 4, or at least 1 insulin prescription within 90 days)
Trial: 32093635
Drug: High PPV
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High PPV for type 1 algorithm (ratio of type 1 to type 2 codes ≥ 4, and multiple daily injections with no other glucose‐lowering medication prescription)
Trial: 32093635
Drug: Optimized algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized algorithm (ratio of type 1 to type 2 codes ≥ 4, and at least 1 insulin prescription within 90 days)
Trial: 32211908
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) injection
Trial: 32289159
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily
Trial: 35099359
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-i) with therapist guidance
Trial: 35099359
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-i) without therapist guidance
Trial: 35099359
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control group receiving unguided treatment after a delay
Trial: 34289212
Drug: ConquerFear-Group (CF-G)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ConquerFear-Group (CF-G)
Trial: 33494844
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake (936 mg/day)
Trial: 33494844
Drug: Magnesium intake
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium intake (315 mg/day)
Trial: 33494844
Drug: Phosphorus intake
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphorus intake (1350 mg/day)
Trial: 33494844
Drug: Total calcium
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total calcium intake (1026 mg/day)
Trial: 33494844
Drug: Dietary magnesium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary magnesium intake (331 mg/day)
Trial: 33494844
Drug: Dietary phosphorus
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary phosphorus intake (1402 mg/day)
Trial: 34687053
Drug: Reciproc Blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reciproc Blue (RCB) size 25, 0.08 taper
Trial: 34687053
Drug: XP-endo Shaper
RxNorm normalized name: 2-acetoxy-1, 8-cineole, (+)-endo-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP-endo Shaper (XPS) size 30, 0.01 taper
Trial: 34687053
Drug: R-Motion (RM)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-Motion (RM) size 30, 0.04 taper
Trial: 34687053
Drug: HyFlex CM
RxNorm normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Hyflex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyFlex CM (HFX) size 30, 0.04 taper
Trial: 35852825
Drug: Electrochemical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrochemical treatment (EC) + AU
Trial: 35852825
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (contaminated without any treatment)
Trial: 39271521
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg twice daily
Trial: 34083384
Drug: GPR84 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPR84 and FFAR4 agonists
Trial: 33606782
Drug: Public health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Public health measures (masking, physical distancing, contact tracing app, willingness to take a COVID-19 vaccine)
Trial: 33405082
Drug: EGCG150 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG150 (150 mg/kg EGCG)
Trial: 33939887
Drug: Curcumin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin and other polyphenol extracts (turmeric, red clover, flaxseed, resveratrol) at a dosage of 3 capsules/day (296.4 mg phenolics/capsule) for 5 ± 2 days before surgery
Trial: 33939887
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no capsules)
Trial: 32819312
Drug: Folate-oriented tertiary
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate-oriented tertiary interventions including assessments of folate status and metabolism, folate intake guidance, and re-evaluation of folate status to ensure red blood cell folate level above 400 ng/ml before pregnancy.
Trial: 33571817
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of urinary cadmium concentration (median = 0.20; 25th, 75th = 0.13, 0.32 μg cadmium/g creatinine)
Trial: 34435371
Drug: MK-8507 200
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8507 200 mg
Trial: 34435371
Drug: MK-8507 800
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8507 800 mg
Trial: 33606754
Drug: Forearm intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forearm intravenous regional anaesthesia (IVRA)
Trial: 33044849
Drug: Concurrent aerobic-resistance
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent aerobic-resistance (A-R) training
Trial: 33044849
Drug: Concurrent resistance-aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent resistance-aerobic (R-A) training
Trial: 33044849
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (CT) (both A-R and R-A)
Trial: 32090730
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (open practices)
Trial: 32090730
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment or placebo)
Trial: 33547808
Drug: L‐PRF+IBB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐PRF+IBB
Trial: 32265255
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (IDet) plus short acting insulin Novolin‐R before three meals (RRR‐IDet plan)
Trial: 33340081
Drug: PBMT (Photobiomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT (Photobiomodulation therapy)
Trial: 33595486
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg/kg body weight) as an additive in peribulbar block
Trial: 32553818
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GLS and ejection fraction
Trial: 33933894
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg buprenorphine
Trial: 32272516
Drug: HP/TAZ lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP/TAZ lotion (halobetasol propionate 0.01%/tazarotene 0.045%)
Trial: 32677156
Drug: Autologous umbilical
RxNorm normalized name: Autologous umbilical cord blood
DrugBank: Autologous cord blood (DB17926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous umbilical cord blood (UCB) stem‐cell therapy
Trial: 34185582
Drug: FDM-informed manual
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDM-informed manual therapy
Trial: 34155501
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with capecitabine (1,000 mg/m2 b.i.d for 14 days) and intravenous cisplatin (75 mg/m2 at day 1, every 3 weeks)
Trial: 33661958
Drug: Arms only
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arms only exercise (upper body rowing exercise) performed with the same prescription as whole-body exercise.
Trial: 32029509
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m2 administered on days 1, 4, and 8 of each chemotherapy course.
Trial: 32029509
Drug: Bortezomib with
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib with standard chemotherapy.
Trial: 32029509
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy without bortezomib.
Trial: 33020094
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy combined with medication (CBT+M)
Trial: 33020094
Drug: Medication-only group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-only group (M)
Trial: 33172941
Drug: Intravenous desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous desmopressin 20 μg in 50 mL sodium chloride 0.9% infused over 20 min
Trial: 33172941
Drug: Intravenous desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous desmopressin
Trial: 35262556
Drug: Tooth bleaching
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth bleaching treatment
Trial: 35262556
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with tooth color satisfaction and self‐perceived oral health
Trial: 35864625
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) - 25 mg/kg bolus followed by 1 mg/kg/hour infusion
Trial: 36263691
Drug: Agomelatine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine therapy (AT) with cognitive behavior therapy (CBT)
Trial: 36263691
Drug: Agomelatine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine therapy (AT) without cognitive behavior therapy (CBT)
Trial: 33198760
Drug: PM2.5 exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM2.5 exposure (mean: 37.8 μg/m3, SD 6.5)
Trial: 33198760
Drug: Filtered air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtered air (mean: 2.1 μg/m3, SD 2.6)
Trial: 33227646
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg DHA/day
Trial: 34552200
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DHA/day
Trial: 32570710
Drug: Sugarcane flour
RxNorm normalized name: Sugarcane
DrugBank: Sugarcane (DB10906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugarcane flour (3 g per day)
Trial: 32570710
Drug: Cellulose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulose placebo (3 g per day)
Trial: 35096107
Drug: Qinpi Tongfeng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinpi Tongfeng Formula (QPTFF) combined with bloodletting therapy
Trial: 35096107
Drug: Colchicine tablets
RxNorm normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine tablets
Trial: 34642699
Drug: mRNA-1273 25
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 25 MCG/0.25 ML Injectable Suspension, 6m through 5y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 25 μg
Trial: 34642699
Drug: mRNA-1273 100
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 100 MCG/0.5 ML Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 100 μg
Trial: 32663912
Drug: mRNA-1273 250
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 250 μg
Trial: 34560797
Drug: MAKS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAKS intervention (Motor, Activities of daily living, Cognitive and Social-communicative component) implemented in DCC
Trial: 34622665
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of statin therapy and vorapaxar
Trial: 32814661
Drug: 5 mg/ml
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/ml fibrinogen and 25 U/ml thrombin (physiological as a control)
Trial: 32814661
Drug: 40 mg/ml
RxNorm normalized name: fiber 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/ml fibrinogen and 250 U/ml thrombin (low adhesive)
Trial: 32814661
Drug: 80 mg/ml
RxNorm normalized name: urea 180 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/ml fibrinogen and 250 U/ml thrombin (high adhesive)
Trial: 35387238
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg twice a day before chemotherapy
Trial: 32005277
Drug: Adaptive Servo-Ventilation
RxNorm normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adaptive Servo-Ventilation (ASV) therapy
Trial: 35109526
Drug: Doll therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doll therapy (DT)
Trial: 32194222
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (2,700 mg/day)
Trial: 36042488
Drug: 4% tetrasodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% tetrasodium EDTA (KiteLock Sterile Locking Solution™)
Trial: 36042488
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (normal saline as a catheter locking solution)
Trial: 32353277
Drug: Multisystemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic therapy (3-5 months) followed by management as usual
Trial: 33931067
Drug: ACL repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACL repair using cortical button fixation and additional suture augmentation
Trial: 35451359
Drug: Liver meat
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver meat balls (LMB) supplement 3 times a week for 90 days
Trial: 35717050
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated and image guided radiation therapy (RT) with a dose of 50.4 Gy to primary PTV and 42 Gy to lymph node PTV, delivered over 28 fractions, with chemotherapy.
Trial: 35717050
Drug: Customized immobilization
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized immobilization device and daily image guided RT.
Trial: 32920824
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (TCS)
Trial: 32920824
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topical corticosteroid (TCS) and NB-UVB
Trial: 32634435
Drug: Drug abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug abuse
Trial: 34228505
Drug: Calaspargase (2,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calaspargase (2,500 IU/m2/dose, every 3 weeks for 10 doses)
Trial: 34228505
Drug: Pegaspargase (2,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegaspargase (2,500 IU/m2/dose, every 2 weeks for 15 doses)
Trial: 35841057
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nanofat subcutaneously and SVF intradermally
Trial: 32703623
Drug: ReDS-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReDS-guided therapy
Trial: 33712909
Drug: Balneological outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneological outpatient treatment (hydrotherapy and peloidotherapy)
Trial: 36262374
Drug: PEMF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEMF therapy (1 mT for 10 min weekly for 16 weeks)